Setting

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2020-2027 by Treatment Type (Medication, Stem Cell Therapy, Others), ALS Type (Sporadic, Familial), Distribution Channel, and Region: Trend Outlook and Growth Opportunity

Published: 30 Jun 2021 | Report Code: 10248048 | Pages: 139

Global amyotrophic lateral sclerosis treatment market will reach $762.3 million by 2027, growing by 5.8% annually over 2020-2027 owing to the increasing geriatric population worldwide coupled with growing prevalence rate of ALS, and the increase in R&D for new amyotrophic lateral sclerosis therapies. Highlighted with 80 tables and 67 figures, this 139-page report “Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2020-2027 by Treatment Type (Medication, Stem Cell Therapy, Others), ALS Type (Sporadic, Familial), Distribution Channel, and Region: Trend Outlook and Growth Opportunity” is based on a comprehensive research of the entire global amyotrophic lateral sclerosis treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global amyotrophic lateral sclerosis treatment market in every aspect of the classification from perspectives of Treatment Type, ALS Type, Distribution Channel, and Region. Based on Treatment Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Medication o Riluzole (Rilutek) o Radicava (Edaravone) o Tiglutik (Thickened Riluzole) o Nuedexta • Stem Cell Therapy • Other Treatments Based on ALS Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Sporadic ALS • Familial ALS Based on Distribution Channel, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies • Other Distribution Channels Geographically, the following regions together with the listed national/local markets are fully investigated: • APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) • Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland) • North America (U.S., Canada, and Mexico) • South America (Brazil, Chile, Argentina, Rest of South America) • MEA (UAE, Saudi Arabia, South Africa) For each aforementioned region and country, detailed analysis and data for annual revenue ($ mn) are available for 2017-2027. The breakdown of all regional markets by country and split of key national markets by Treatment Type, ALS Type, and Distribution Channel over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Key Players (this may not be a complete list and extra companies can be added upon request): AB Science SA Amylyx Pharmaceuticals Inc. Biogen Inc. Biohaven Pharmaceutical Holding Co., Ltd. BrainStorm Cell Limited Corestem, Inc. F.Hoffmann-La Roche AG Ionis Pharmaceuticals, Inc. Mitsubishi Tanabe Pharma Corporation Otsuka Pharmaceutical Co., Ltd. Sun Pharmaceutical Industries Ltd. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents

1 Introduction	9
1.1 Industry Definition and Research Scope	9
1.1.1 Industry Definition	9
1.1.2 Research Scope	10
1.2 Research Methodology	13
1.2.1 Overview of Market Research Methodology	13
1.2.2 Market Assumption	14
1.2.3 Secondary Data	14
1.2.4 Primary Data	14
1.2.5 Data Filtration and Model Design	15
1.2.6 Market Size/Share Estimation	16
1.2.7 Research Limitations	17
1.3 Executive Summary	18
2 Market Overview and Dynamics	20
2.1 Market Size and Forecast	20
2.1.1 Impact of COVID-19 on World Economy	21
2.1.2 Impact of COVID-19 on the Market	23
2.2 Major Growth Drivers	25
2.3 Market Restraints and Challenges	29
2.4 Emerging Opportunities and Market Trends	32
2.5 Porter’s Fiver Forces Analysis	36
3 Segmentation of Global Market by Treatment Type	40
3.1 Market Overview by Treatment Type	40
3.2 Medication	42
3.3 Stem Cell Therapy	44
3.4 Other Treatments	45
4 Segmentation of Global Market by ALS Type	46
4.1 Market Overview by ALS Type	46
4.2 Sporadic ALS	48
4.3 Familial ALS	49
5 Segmentation of Global Market by Distribution Channel	50
5.1 Market Overview by Distribution Channel	50
5.2 Hospital Pharmacies	52
5.3 Retail Pharmacies	53
5.4 Online Pharmacies	54
5.5 Other Distribution Channels	55
6 Segmentation of Global Market by Region	56
6.1 Geographic Market Overview 2020-2027	56
6.2 North America Market 2020-2027 by Country	60
6.2.1 Overview of North America Market	60
6.2.2 U.S.	63
6.2.3 Canada	66
6.2.4 Mexico	68
6.3 European Market 2020-2027 by Country	70
6.3.1 Overview of European Market	70
6.3.2 UK	73
6.3.3 France	75
6.3.4 Germany	77
6.3.5 Spain	79
6.3.6 Italy	81
6.3.7 Russia	83
6.3.8 Rest of European Market	85
6.4 Asia-Pacific Market 2020-2027 by Country	87
6.4.1 Overview of Asia-Pacific Market	87
6.4.2 China	90
6.4.3 Japan	92
6.4.4 India	95
6.4.5 Australia	97
6.4.6 South Korea	99
6.4.7 Rest of APAC Region	101
6.5 South America Market 2020-2027 by Country	103
6.5.1 Argentina	106
6.5.2 Brazil	108
6.5.3 Chile	110
6.5.4 Rest of South America Market	112
6.6 MEA Market 2020-2027 by Country	113
6.6.1 UAE	116
6.6.2 Saudi Arabia	118
6.6.3 South Africa	120
6.6.4 Other National Markets	122
7 Competitive Landscape	123
7.1 Overview of Key Vendors	123
7.2 New Product Launch, Partnership, Investment, and M&A	126
7.3 Company Profiles	127
AB Science SA	127
Amylyx Pharmaceuticals Inc.	129
Biogen Inc.	130
Biohaven Pharmaceutical Holding Co., Ltd.	131
BrainStorm Cell Limited	132
Corestem, Inc.	133
F.Hoffmann-La Roche AG	134
Ionis Pharmaceuticals, Inc.	135
Mitsubishi Tanabe Pharma Corporation	136
Otsuka Pharmaceutical Co., Ltd.	137
Sun Pharmaceutical Industries Ltd.	138
RELATED REPORTS	139
List Of Tables

Table 1.  Snapshot of Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Balanced Perspective, 2020-2027	19
Table 2. Growth Rate of World GDP, 2020-2022	22
Table 3.  Main Product Trends and Market Opportunities in Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market	32
Table 4. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn	40
Table 5. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Medication by Type, 2017-2027, $ mn	43
Table 6. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn	46
Table 7. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn	50
Table 8. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Region, 2017-2027, $ mn	57
Table 9.  Leading National Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2020 and 2027, $ mn	59
Table 10. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2017-2027, $ mn	62
Table 11. U.S. Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn	65
Table 12. U.S. Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn	65
Table 13. U.S. Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn	65
Table 14. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn	67
Table 15. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn	67
Table 16. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn	67
Table 17. Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn	69
Table 18. Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn	69
Table 19. Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn	69
Table 20. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2017-2027, $ mn	72
Table 21. UK Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn	74
Table 22. UK Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn	74
Table 23. UK Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn	74
Table 24. France Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn	76
Table 25. France Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn	76
Table 26. France Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn	76
Table 27. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn	78
Table 28. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn	78
Table 29. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn	78
Table 30. Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn	80
Table 31. Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn	80
Table 32. Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn	80
Table 33. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn	82
Table 34. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn	82
Table 35. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn	82
Table 36. Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn	84
Table 37. Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn	84
Table 38. Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn	84
Table 39. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Rest of Europe by Country, 2017-2027, $ mn	86
Table 40. APAC Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2017-2027, $ mn	89
Table 41. China Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn	91
Table 42. China Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn	91
Table 43. China Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn	91
Table 44. Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn	94
Table 45. Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn	94
Table 46. Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn	94
Table 47. India Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn	96
Table 48. India Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn	96
Table 49. India Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn	96
Table 50. Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn	98
Table 51. Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn	98
Table 52. Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn	98
Table 53. South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn	100
Table 54. South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn	100
Table 55. South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn	100
Table 56. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Rest of APAC by Country/Region, 2017-2027, $ mn	102
Table 57. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2017-2027, $ mn	105
Table 58. Argentina Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn	107
Table 59. Argentina Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn	107
Table 60. Argentina Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn	107
Table 61. Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn	109
Table 62. Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn	109
Table 63. Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn	109
Table 64. Chile Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn	111
Table 65. Chile Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn	111
Table 66. Chile Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn	111
Table 67. MEA Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2017-2027, $ mn	115
Table 68. UAE Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn	117
Table 69. UAE Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn	117
Table 70. UAE Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn	117
Table 71. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn	119
Table 72. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn	119
Table 73. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn	119
Table 74. South Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn	121
Table 75. South Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn	121
Table 76. South Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn	121
Table 77. AB Science SA: Company Snapshot	127
Table 78. AB Science SA: Business Segmentation	127
Table 79. AB Science SA: Product Portfolio	128
Table 80. AB Science SA: Revenue, 2017-2019, $ mn	128
List Of Figures

Figure 1. Research Method Flow Chart	13
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation	16
Figure 3. Global Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2027	18
Figure 4. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2017-2027, $ mn	20
Figure 5. Impact of COVID-19 on Business	23
Figure 6. Primary Drivers and Impact Factors of Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market	25
Figure 7.  Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million	28
Figure 8. Primary Restraints and Impact Factors of Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market	29
Figure 9. Investment Opportunity Analysis	33
Figure 10. Porter’s Fiver Forces Analysis of Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market	36
Figure 11. Breakdown of Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2020-2027, % of Revenue	40
Figure 12. Contribution to Global 2021-2027 Cumulative Revenue by Treatment Type, Value ($ mn) and Share (%)	41
Figure 13. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Medication, 2017-2027, $ mn	42
Figure 14. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Stem Cell Therapy, 2017-2027, $ mn	44
Figure 15. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Other Treatments, 2017-2027, $ mn	45
Figure 16. Breakdown of Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2020-2027, % of Revenue	46
Figure 17. Contribution to Global 2021-2027 Cumulative Revenue by ALS Type, Value ($ mn) and Share (%)	47
Figure 18. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Sporadic ALS, 2017-2027, $ mn	48
Figure 19. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Familial ALS, 2017-2027, $ mn	49
Figure 20. Breakdown of Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2020-2027, % of Revenue	51
Figure 21. Contribution to Global 2021-2027 Cumulative Revenue by Distribution Channel, Value ($ mn) and Share (%)	51
Figure 22. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Hospital Pharmacies, 2017-2027, $ mn	52
Figure 23. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Retail Pharmacies, 2017-2027, $ mn	53
Figure 24. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Online Pharmacies, 2017-2027, $ mn	54
Figure 25. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Other Distribution Channels, 2017-2027, $ mn	55
Figure 26.  Global Market Snapshot by Region	56
Figure 27.  Geographic Spread of Worldwide Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2020-2027, % of Revenue	57
Figure 28. Contribution to Global 2021-2027 Cumulative Revenue by Region, Value ($ mn) and Share (%)	58
Figure 29.  North American Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2017-2027, $ mn	61
Figure 30. Breakdown of North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2020 and 2027, % of Revenue	61
Figure 31. Contribution to North America 2021-2027 Cumulative Revenue by Country, Value ($ mn) and Share (%)	62
Figure 32. U.S. Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2017-2027, $ mn	64
Figure 33. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2017-2027, $ mn	66
Figure 34.  Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Mexico, 2017-2027, $ mn	68
Figure 35.  European Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2017-2027, $ mn	71
Figure 36. Breakdown of European Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2020 and 2027, % of Revenue	71
Figure 37. Contribution to Europe 2021-2027 Cumulative Revenue by Country, Value ($ mn) and Share (%)	72
Figure 38.  Amyotrophic Lateral Sclerosis (ALS) Treatment Market in UK, 2017-2027, $ mn	73
Figure 39.  Amyotrophic Lateral Sclerosis (ALS) Treatment Market in France, 2017-2027, $ mn	75
Figure 40.  Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Germany, 2017-2027, $ mn	77
Figure 41.  Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Spain, 2017-2027, $ mn	79
Figure 42.  Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Italy, 2017-2027, $ mn	81
Figure 43.  Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Russia, 2017-2027, $ mn	83
Figure 44.  Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Rest of Europe, 2017-2027, $ mn	85
Figure 45. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2017-2027, $ mn	88
Figure 46. Breakdown of APAC Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2020 and 2027, % of Revenue	88
Figure 47. Contribution to APAC 2021-2027 Cumulative Revenue by Country, Value ($ mn) and Share (%)	89
Figure 48.  Amyotrophic Lateral Sclerosis (ALS) Treatment Market in China, 2017-2027, $ mn	90
Figure 49.  Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Japan, 2017-2027, $ mn	93
Figure 50.  Amyotrophic Lateral Sclerosis (ALS) Treatment Market in India, 2017-2027, $ mn	95
Figure 51.  Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Australia, 2017-2027, $ mn	97
Figure 52.  Amyotrophic Lateral Sclerosis (ALS) Treatment Market in South Korea, 2017-2027, $ mn	99
Figure 53.  Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Rest of APAC, 2017-2027, $ mn	101
Figure 54. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2017-2027, $ mn	104
Figure 55. Breakdown of South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2020 and 2027, % of Revenue	104
Figure 56. Contribution to South America 2021-2027 Cumulative Revenue by Country, Value ($ mn) and Share (%)	105
Figure 57.  Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Argentina, 2017-2027, $ mn	106
Figure 58.  Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Brazil, 2017-2027, $ mn	108
Figure 59.  Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Chile, 2017-2027, $ mn	110
Figure 60.  Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Rest of South America, 2017-2027, $ mn	112
Figure 61. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Middle East and Africa (MEA), 2017-2027, $ mn	114
Figure 62. Breakdown of MEA Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2020 and 2027, % of Revenue	114
Figure 63. Contribution to MEA 2021-2027 Cumulative Revenue by Country, Value ($ mn) and Share (%)	115
Figure 64.  Amyotrophic Lateral Sclerosis (ALS) Treatment Market in UAE, 2017-2027, $ mn	116
Figure 65.  Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Saudi Arabia, 2017-2027, $ mn	118
Figure 66.  Amyotrophic Lateral Sclerosis (ALS) Treatment Market in South Africa, 2017-2027, $ mn	120
Figure 67. Growth Stage of Global Amyotrophic Lateral Sclerosis (ALS) Treatment Industry over the Forecast Period	123

Key Players (this may not be a complete list and extra companies can be added upon request): 
AB Science SA
Amylyx Pharmaceuticals Inc.
Biogen Inc.
Biohaven Pharmaceutical Holding Co., Ltd.
BrainStorm Cell Limited
Corestem, Inc.
F.Hoffmann-La Roche AG
Ionis Pharmaceuticals, Inc.
Mitsubishi Tanabe Pharma Corporation
Otsuka Pharmaceutical Co., Ltd.
Sun Pharmaceutical Industries Ltd.
 (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)